Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.590
+0.020 (0.44%)
At close: Mar 6, 2026, 4:00 PM EST
4.450
-0.140 (-3.05%)
After-hours: Mar 6, 2026, 7:53 PM EST
Nuvation Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 62.9 | 7.87 | - | - | - | |
| Revenue Growth (YoY) | 698.96% | - | - | - | - | |
| Cost of Revenue | 9.3 | 7.08 | - | - | - | |
| Gross Profit | 53.6 | 0.8 | - | - | - | |
| Selling, General & Admin | 151.56 | 69.23 | 28.53 | 31.92 | 24.28 | |
| Research & Development | 115.11 | 99.12 | 71.29 | 87.82 | 65.25 | |
| Operating Expenses | 266.67 | 168.35 | 99.82 | 119.73 | 89.53 | |
| Operating Income | -213.06 | -167.56 | -99.82 | -119.73 | -89.53 | |
| Interest Expense | -13.68 | -0.34 | - | - | - | |
| Interest & Investment Income | 21.43 | 27.06 | 24.61 | 7.45 | 2.96 | |
| Other Non Operating Income (Expenses) | 0.72 | -2.02 | -0.45 | 9.32 | 3.59 | |
| EBT Excluding Unusual Items | -204.6 | -142.86 | -75.66 | -102.97 | -82.98 | |
| Gain (Loss) on Sale of Investments | 0.01 | -0.01 | -0.14 | -1.23 | -0.08 | |
| Gain (Loss) on Sale of Assets | -0.03 | - | - | - | - | |
| Pretax Income | -204.63 | -567.94 | -75.8 | -104.2 | -86.85 | |
| Net Income | -204.63 | -567.94 | -75.8 | -104.2 | -86.85 | |
| Net Income to Common | -204.63 | -567.94 | -75.8 | -104.2 | -86.85 | |
| Shares Outstanding (Basic) | 342 | 269 | 219 | 217 | 198 | |
| Shares Outstanding (Diluted) | 342 | 269 | 219 | 217 | 198 | |
| Shares Change (YoY) | 27.07% | 22.79% | 1.00% | 9.52% | 102.90% | |
| EPS (Basic) | -0.60 | -2.11 | -0.35 | -0.48 | -0.44 | |
| EPS (Diluted) | -0.60 | -2.11 | -0.35 | -0.48 | -0.44 | |
| Free Cash Flow | -173.78 | -130.58 | -68.07 | -96.48 | -68.47 | |
| Free Cash Flow Per Share | -0.51 | -0.49 | -0.31 | -0.45 | -0.35 | |
| Gross Margin | 85.22% | 10.10% | - | - | - | |
| Operating Margin | -338.72% | -2128.25% | - | - | - | |
| Profit Margin | -325.31% | -7213.76% | - | - | - | |
| Free Cash Flow Margin | -276.27% | -1658.52% | - | - | - | |
| EBITDA | -211.33 | -166.87 | -99.6 | -119.54 | -89.35 | |
| D&A For EBITDA | 1.74 | 0.68 | 0.22 | 0.2 | 0.18 | |
| EBIT | -213.06 | -167.56 | -99.82 | -119.73 | -89.53 | |
| Revenue as Reported | 62.9 | 7.87 | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.